Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Chemother ; 34(7): 419-426, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-35550007

RESUMEN

Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA) are new possibilities of antimicrobial treatment that combined a ß-lactam with a ß-lactamase inhibitor. The United States (US) and European regulatory agencies approved their clinical use in adults with complicated intra-abdominal infections. This study aims to know if one of the two antibiotics obtain better efficacy in adults with complicated intra-abdominal infections and by specific pathogens such as P. aeruginosa or E. coli. A search of all trials in MEDLINE, Scopus, and Web of Science comparing a C/T or CZA based antimicrobial regimen with other treatments in patients with intraabdominal infections until August 2021 was performed. To make indirect comparisons, we used a frequentist approach using the R package netmeta.The effects have been expressed through the relative risk (RR) with its confidence interval. Considering the clinical cure and failure rates between the different trial populations (mMITT, CE, ME) and the mortality at the end of the study, we have not found significant differences between CZA and C/T. In the case of Pseudomonas, the RR of treatment failure between these two antibiotics is 1 (95% CI 0.55-1.18). In the case of E. Coli, although it seems that CZA would have a worse result than C/T, differences did not reach statistical significance (RR1.06; 95% CI 0.9-1.14). In conclusion, we have not found statistically significant differences between ceftolozane-tazobactam and ceftazidime-avibactam in treating cIAI. In regards to E. Coli, our results do not reach significance, but it would be possible that C/T and meropenem had better results than CZA. Perhaps new trials would allow a better profile of the role in different types of patients or infections caused by specific microorganisms in the future.


Asunto(s)
Infecciones Intraabdominales , Infecciones por Pseudomonas , Adulto , Humanos , Ceftazidima/uso terapéutico , Ceftazidima/farmacología , Inhibidores de beta-Lactamasas/uso terapéutico , Meropenem/farmacología , Escherichia coli , Compuestos de Azabiciclo/uso terapéutico , Compuestos de Azabiciclo/farmacología , Cefalosporinas/uso terapéutico , Cefalosporinas/farmacología , Tazobactam/uso terapéutico , Tazobactam/farmacología , Infecciones Intraabdominales/tratamiento farmacológico , Combinación de Medicamentos , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Pseudomonas aeruginosa , Pruebas de Sensibilidad Microbiana , Infecciones por Pseudomonas/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA